February 19, 2017 11:32 PM ET


Company Overview of PaxVax Corporation

Company Overview

PaxVax Corporation researches, develops, manufactures, and commercializes vaccines against various infectious diseases. Its products include PXVX0200, a single-dose oral vaccine against cholera; Vivotif, a typhoid fever vaccine for oral administration; Epaxal, a vaccine for hepatitis A; PXVX0103, an oral adenoviral-based vaccine against avian influenza (H5N1) or bird flu; a single-dose oral vaccine candidate for protection against anthrax; Ad4-env Clade C, a HIV vaccine component that expresses an optimized HIV envelope protein derived from a Clade C HIV strain; and Ad4-mGag, a HIV vaccine component that expresses an optimized HIV gag protein. The company also engages in the research and dev...

900 Veterans Boulevard

Suite 500

Redwood City, CA 94063

United States

Founded in 2006





Key Executives for PaxVax Corporation

Chief Executive Officer, President and Director
Chief Financial Officer and Executive Vice President
Age: 64
Chief Scientific Officer and Executive Vice President
Chief Legal Officer and Executive Vice President
Chief Medical Officer
Age: 77
Compensation as of Fiscal Year 2016.

PaxVax Corporation Key Developments

PaxVax Partners with National Institutes of Health and Department of Defense to Develop a New Virus-Like Particle Vaccine to Fight the Spread of Chikungunya

PaxVax announced its partnership with the National Institutes of Health (NIH) and United States Department of Defense (DoD) on its chikungunya vaccine program. According to the terms of the collaboration, PaxVax has in-licensed the NIH virus-like particle (VLP) vaccine technology for chikungunya with plans to bring the vaccine through full commercialization. NIH has already completed a phase 1 trial, and is currently assessing the vaccine in a phase 2 trial. For the past year, PaxVax has been working to develop a commercial manufacturing process and the necessary release assays. In addition to conducting its own trials, PaxVax will work with the Walter Reed Army Institute of Research (WRAIR)—a DoD biomedical research laboratory—to conduct an additional clinical trial to assess the potential advantages of an alum adjuvant in the vaccine formulation.

PaxVax Announces the Availability of Vaxchora™ in the United States

PaxVax Inc. announced that Vaxchora™ is now available in the United States (U.S.) as the country's only vaccine for protection against cholera, a highly contagious intestinal diarrheal infection that can cause death in less than 24 hours if left untreated. Vaxchora, a single-dose vaccine, was approved by the U.S. Food and Drug Administration (FDA) in June 2016 for use in U.S. adults traveling to cholera-affected areas as an active immunization against disease caused by Vibrio cholerae serogroup O1. Also in June 2016, The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously to recommend Vaxchora for travelers to areas of active cholera transmission. Estimated to be widespread in 69 countries, primarily in Africa, Asia, and the Caribbean, cholera is acquired by ingesting contaminated water or food. Annually, millions of people around the world are impacted by this extremely infectious disease. A recent report from the CDC suggests that the true number of cholera cases in the U.S. is at least 30 times higher than observed by national surveillance systems. Non-vaccine intervention to prevent cholera infection is the avoidance of contaminated water and food, but studies have shown that 98% of travelers do not comply with these precautions when travelling.

PaxVax, Inc. Appoints Philip K. Moody as Chief Financial Officer

PaxVax Inc. announced the appointment of Philip K. Moody as Chief Financial Officer (CFO) effective August 29, 2016. In this role, Mr. Moody will oversee all financial functions for the company. Mr. Moody joins PaxVax from BTG PLC, where he served as the Chief Financial Officer for the North American sector. In this role, he served as an advisor to the Head of North America at BTG, and was responsible for management and oversight of all financial functions for the British-based medical device/specialty pharmaceutical business. Mr. Moody has also held senior finance roles in a number of public and private companies, including Chiron, where he was involved in their vaccines business and served as Vice President, Finance and Operations.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PaxVax Corporation, please visit www.paxvax.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.